AdvanCell Revenue and Competitors
Estimated Revenue & Valuation
- AdvanCell's estimated annual revenue is currently $5.4M per year.
- AdvanCell's estimated revenue per employee is $155,000
Employee Data
- AdvanCell has 35 Employees.
- AdvanCell grew their employee count by 52% last year.
AdvanCell's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Production | Reveal Email/Phone |
2 | Engineering Development Manager | Reveal Email/Phone |
AdvanCell Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $376.5M | 2429 | 9% | N/A | N/A |
#2 | $1.1M | 7 | -22% | N/A | N/A |
#3 | $7.5M | 61 | 20% | $106.1M | N/A |
#4 | $11.3M | 73 | N/A | N/A | N/A |
#5 | $18.6M | 120 | 33% | N/A | N/A |
#6 | $20.3M | 131 | 7% | N/A | N/A |
#7 | $1.7M | 11 | -72% | N/A | N/A |
#8 | $69.3M | 447 | 37% | N/A | N/A |
#9 | $28.7M | 185 | 5% | N/A | N/A |
#10 | $25M | 161 | 55% | N/A | N/A |
What Is AdvanCell?
AdvanCell is a radiopharmaceutical company developing an innovative pipeline of 212Pb-based Targeted Alpha Therapies for cancer patients. AdvanCell’s platform technology addresses the most significant challenge in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell’s novel drug discovery, preclinical processes, and state-of-the-art facilities leverage daily access to 212Pb, the ideal isotope for Targeted Alpha Therapy. For more information, please visit www.advancell.com.au
keywords:N/A
N/A
Total Funding
35
Number of Employees
$5.4M
Revenue (est)
52%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Sydney
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 35 | -10% | N/A |
#2 | $7.1M | 35 | -20% | N/A |
#3 | $7.1M | 35 | -3% | N/A |
#4 | $6.2M | 35 | -5% | N/A |
#5 | $3.5M | 35 | -26% | $70.2M |